Search

Your search keyword '"Regateiro, Frederico S."' showing total 243 results

Search Constraints

Start Over You searched for: Author "Regateiro, Frederico S." Remove constraint Author: "Regateiro, Frederico S."
243 results on '"Regateiro, Frederico S."'

Search Results

1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

2. MASK-air: An OECD (Organisation for Economic Co-operation and Development) Best Practice for Public Health on Integrated Care for Chronic Diseases

3. Poor Rhinitis and Asthma Control Is Associated With Decreased Health-Related Quality of Life and Utilities: A MASK-air Study

4. Impairment of EQ-5D-5L Domains According to Allergic Rhinitis and Asthma Control: A MASK-air Real-World Study

5. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study

6. Cutoff Values of MASK-air Patient-Reported Outcome Measures

7. Academic Productivity of Young People With Allergic Rhinitis: A MASK-air Study

8. The Allergic Rhinitis and Its Impact on Asthma (ARIA) Approach of Value-Added Medicines: As-Needed Treatment in Allergic Rhinitis

9. The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EAACI Perspective

10. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis:A MASK-air study

11. Regional, sex, and age inequities in asthma hospital admissions in Spain and Portugal

12. Poor rhinitis and asthma control is associated with decreased health-related quality-of-life and utilities: A MASK-air study

13. MASK-air®: An OECD (Organisation for Economic Coordination and Development) Best Practice for Public Health on integrated care for chronic diseases.

15. Relevance of individual bronchial symptoms for asthma diagnosis and control in patients with rhinitis: A MASK‐air study.

17. Patient‐centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA‐EAACI approach – ARIA‐EAACI Task Force Report

18. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach.

19. Consistent trajectories of rhinitis control and treatment in 16,177 weeks : the MASK-air® longitudinal study

20. Patient-centered digital biomarkers for allergic respiratory diseases and asthma:The ARIA-EAACI approach – ARIA-EAACI Task Force Report

21. Patient‐centred digital biomarkers for allergic respiratory diseases and asthma: the ARIA‐EAACI approach

22. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air (R) longitudinal study

23. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

24. Development and validation of an electronic daily control score for asthma (e-DASTHMA):a real-world direct patient data study

25. Consistent trajectories of rhinitis control and treatment in 16,177 weeks

26. MASK‐air® direct patient data support the ARIA‐MeDALL hypothesis on allergic phenotypes.

27. Digitally‐enabled, patient‐centred care in rhinitis and asthma multimorbidity: The ARIA‐MASK‐air ® approach

28. The ARIA-MASK-air® approach

29. Rhinitis associated with asthma is distinct from rhinitis alone: TARIA‐MeDALL hypothesis

30. Cutoff Values of MASK-air Patient-Reported Outcome Measures

31. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK‐air® longitudinal study

33. Real‐world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

35. A study using MASK-air® real-world data

36. Allergies and COVID-19 vaccines : An ENDA/EAACI Position paper

37. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference

38. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air real-world data.

39. Development and validation of combined symptom-medication scores for allergic rhinitis*

40. Consistent trajectories of rhinitis control and treatment in 16,177 weeks: The MASK-air® longitudinal study.

41. Comparison of rhinitis treatments using MASK-air® data and considering the minimal important difference.

42. Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities

43. Allergies and COVID-19 vaccines:An ENDA/EAACI Position paper

44. Comparison of rhinitis treatments using MASK-air (R) data and considering the minimal important difference

45. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model

46. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air(R) real-world data

48. Comparison of rhinitis treatments using MASK ‐air® data and considering the minimal important difference

50. Results of a Bayesian mixed-effects model

Catalog

Books, media, physical & digital resources